Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy DOI Creative Commons
Diana V. Yuzhakova, Daria A. Sachkova, Anna V. Izosimova

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(2), P. 97 - 97

Published: Jan. 10, 2025

Background: The wide variability in clinical responses to anti-tumor immunotherapy drives the search for personalized strategies. One of promising approaches is drug screening using patient-derived models composed tumor and immune cells. In this regard, selection an appropriate vitro model choice cellular response assay are critical reliable predictions. Fluorescence lifetime imaging microscopy (FLIM) a powerful, non-destructive tool that enables direct monitoring metabolism on label-free basis with potential resolve metabolic rearrangements cells associated their reactivity. Objective: aim study was develop glioma explant enriched by autologous peripheral lymphocytes explore FLIM redox-cofactor NAD(P)H living measure checkpoint inhibitors. Methods: light microscopy, flow cytometry were used. Results: results demonstrate responsive displayed significant increase free fraction α1 after treatment, shift towards glycolysis due lymphocyte activation. non-responsive exhibited no alterations or decrease treatment. data correlated well standard assays vitro, including morphological changes, T-cells activation marker CD69, cell proliferation index Ki67. Conclusions: proposed platform includes explants co-cultured represents solution patient-specific immunotherapeutic screening.

Language: Английский

Tumor‐Associated Macrophages Nano‐Reprogrammers Induce “Gear Effect” to Empower Glioblastoma Immunotherapy DOI Open Access
Yang Wang, Guangzhe Li,

Jianlong Su

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Abstract Glioblastoma (GBM), the most malignant brain tumor with high prevalence, remains highly resistant to existing immunotherapies due significant immunosuppression within microenvironment (TME), predominantly manipulated by M2‐phenotypic tumor‐associated macrophages (M2‐TAMs). Here in this work, an M2‐TAMs targeted nano‐reprogrammers, MG5‐S‐IMDQ, is established decorating mannose molecule as targeting moiety well toll‐like receptor (TLR) 7/8 agonist, imidazoquinoline (IMDQ) on dendrimeric nanoscaffold. MG5‐S‐IMDQ demonstrated excellent capacity of penetrating blood‐brain barrier (BBB) selectively GBM microenvironment, leading a phenotype transformation and function restoration TAMs shown heightened phagocytic activity toward cells, enhanced cytotoxic effects, improved antigen cross‐presentation capability. In meantime, induction function‐oriented “gear effect”, treatment extended its impact systemically enhancing infiltration type I conventional dendritic cells (cDC1s) into sites bolstering adaptive immune responses. sum, precisely working unique target situ, nano‐reprogrammers successfully robust network that worked synergistically combat tumors. This facile nanoplatform‐based immunomodulatory strategy, serving powerful convenient monotherapy or complementary alongside other therapies like surgery, provided deep insights for advancing translational study GBM.

Language: Английский

Citations

2
Advancements in targeted and immunotherapy strategies for glioma: toward precision treatment DOI Creative Commons

Guangyuan Gong,

Lang Jiang,

Jing Zhou

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 14, 2025

In recent years, significant breakthroughs have been made in cancer therapy, particularly with the development of molecular targeted therapies and immunotherapies, owing to advances tumor biology immunology. High-grade gliomas (HGGs), characterized by their high malignancy, remain challenging treat despite standard treatment regimens, including surgery, radiotherapy, chemotherapy, treating fields (TTF). These provide limited efficacy, highlighting need for novel strategies. Molecular immunotherapy emerged as promising avenues improving outcomes high-grade gliomas. This review explores current status advancements immunotherapeutic approaches

Language: Английский

Citations

2
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression DOI Creative Commons

Yunna Chen,

Qianqian Zhou,

Zongfang Jia

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(9), P. 3834 - 3854

Published: June 3, 2024

Immunotherapy is an important cancer treatment method that offers hope for curing patients. While immunotherapy has achieved initial success, a major obstacle to its widespread adoption the inability benefit majority of The success or failure closely linked tumor's immune microenvironment. Recently, there been significant attention on strategies regulate tumor microenvironment in order stimulate anti-tumor responses immunotherapy. distinctive physical properties and design flexibility nanomedicines have extensively utilized target cells (including tumor-associated macrophages (TAMs), T cells, myeloid-derived suppressor (MDSCs), fibroblasts (TAFs)), offering promising advancements In this article, we reviewed aimed at targeting various focus models are based nanomedicines, with goal inducing enhancing improve It worth noting combining other treatments, such as chemotherapy, radiotherapy, photodynamic therapy, can maximize therapeutic effects. Finally, identified challenges nanotechnology-mediated needs overcome more effective nanosystems.

Language: Английский

Citations

17
The hidden architects of glioblastoma multiforme: Glioma stem cells DOI Creative Commons
Om Saswat Sahoo,

Rhiti Mitra,

Naveen KH Nagaiah

et al.

MedComm – Oncology, Journal Year: 2024, Volume and Issue: 3(1)

Published: Feb. 1, 2024

Abstract Glioblastoma multiforme (GBM), a WHO grade IV diffuse glioma, is highly aggressive brain tumor with median survival of less than year. Characterized by robust proliferation and invasion, recent studies spotlight glioma stem cells (GSCs) within GBM tumors, pivotal in development, progression, treatment resistance. This review aims to shed light on the critical role GSCs initiation progression GBM, emphasizing their contribution development resistance existing treatments. Unlike normal cells, play pathogenesis. The delves into unique characteristics GSCs, marked heightened metabolic activities distinct epigenetic transcriptional programming. Recognizing significance years, examines how presence amplifies lethal nature GBM. also critically evaluates advancements diagnostic methods therapies, which include targeting GSCs. Providing concise yet comprehensive overview, contributes insights GBM's intricate dynamics, offering potential directions for future research therapeutic strategies.

Language: Английский

Citations

13
Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives DOI
Jiyuan Liu, Fan Yang, Jinqu Hu

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2024, Volume and Issue: 30(5)

Published: May 1, 2024

Abstract Gliomas are the most common primary tumors of central nervous system, with glioblastoma multiforme (GBM) having highest incidence, and their therapeutic efficacy depends primarily on extent surgical resection postoperative chemotherapy. The role intracranial blood–brain barrier occurrence drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited chemotherapeutic agents in patients GBM made it difficult to achieve expected clinical response. In recent years, rapid development nanotechnology has brought new hope for treatment tumors. Nanoparticles (NPs) shown great potential tumor therapy due unique properties such as light, heat, electromagnetic effects, passive targeting. Furthermore, NPs can effectively load drugs, significantly reduce side effects improve efficacy, showing chemotherapy glioma. this article, we reviewed mechanisms glioma drug resistance, physicochemical NPs, advances resistance. We aimed provide perspectives

Language: Английский

Citations

12
Current Photodynamic Therapy for Glioma Treatment: An Update DOI Creative Commons
David Aebisher,

Agnieszka Przygórzewska,

Angelika Myśliwiec

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(2), P. 375 - 375

Published: Feb. 6, 2024

Research on the development of photodynamic therapy for treatment brain tumors has shown promise in this highly aggressive form cancer. Analysis both vivo studies and clinical shows that can provide significant benefits, such as an improved median rate survival. The use is characterized by relatively few side effects, which a advantage compared to conventional methods often-used tumor surgery, advanced radiotherapy, classic chemotherapy. Continued research area could bring advances, influencing future standards difficult deadly disease.

Language: Английский

Citations

11
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives DOI Open Access

Francesca Carosi,

Elisabetta Broseghini,

Laura Fabbri

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(15), P. 2752 - 2752

Published: Aug. 2, 2024

The isocitrate dehydrogenase 1 and 2 (IDH1 IDH2) enzymes are involved in key metabolic processes human cells, regulating differentiation, proliferation, oxidative damage response. IDH mutations have been associated with tumor development progression various solid tumors such as glioma, cholangiocarcinoma, chondrosarcoma, other types become crucial markers molecular classification prognostic assessment. intratumoral serum levels of D-2-hydroxyglutarate (D-2-HG) could serve diagnostic biomarkers for identifying mutant (IDHmut) tumors. As a result, an increasing number clinical trials evaluating targeted treatments IDH1/IDH2 mutations. Recent studies shown that the focus these new therapeutic strategies is not only neomorphic activity IDHmut but also epigenetic shift induced by potential role combination treatments. Here, we provide overview current knowledge about tumors, particular on available IDH-targeted emerging results from aiming to explore tumor-specific features identify benefit therapies their strategies. An insight into future perspectives roles circulating radiomic included.

Language: Английский

Citations

10
LAMB1 downregulation suppresses glioma progression by inhibiting aerobic glycolysis through regulation of the NF-κB/HK2 axis DOI Creative Commons
Zhenxiang Zhao, Haiying Liu, Yingzi Liu

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 7, 2025

Laminin subunit beta 1 (LAMB1) has regulatory functions on the proliferation, attachment, and migration of tumor cells, with increased levels linked to different cancers. This study aims at investigating effects mechanisms LAMB1 in glioma. Glioma cell models overexpression or downregulation were constructed. Cell viability, invasion evaluated. Glucose uptake lactate production examined, Seahorse was used assess extracellular acidification rate (ECAR). The EC50 temozolomide (TMZ) glioma cells tested. Western blotting conducted monitor expression HK1, HK2, PDHA, PKM. Bioinformatic analysis employed investigate downstream mechanism LAMB1. In addition, a subcutaneous model constructed determine influence GBM growth vivo. enhanced promoted growth. upregulation cellular glycolysis repressed sensitivity TMZ. activated NF-κB pathway. Downregulation mitigating pathway by Bay 11-7082 inhibited growth, TMZ sensitivity. exerted antitumor regulating NF-κB/HK2 axis.

Language: Английский

Citations

2
The prognostic significance of epoxide hydrolases in colorectal cancer DOI
Lichao Cao,

Ying Ba,

Fangfang Chen

et al.

Biochemistry and Biophysics Reports, Journal Year: 2025, Volume and Issue: 41, P. 101912 - 101912

Published: Jan. 1, 2025

Language: Английский

Citations

1
Efficient Gene Delivery Admitted by small Metabolites Specifically Targeting Astrocytes in the Mouse Brain DOI

Haibin Zhou,

Jiajing Dai,

Dong Li

et al.

Molecular Therapy, Journal Year: 2025, Volume and Issue: 33(3), P. 1166 - 1179

Published: Jan. 11, 2025

Language: Английский

Citations

1